Intra-Arterial Radionuclide Therapies for Liver Tumors

Bozkurt, Murat Fani; Salancı, Bilge Volkan; Uğur, Ömer

doi:10.1053/j.semnuclmed.2016.01.008

Cited by 42 publications

(36 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The toxicity to normal hepatic tissues is limited because these tissues are primarily supplied by the portal venous system. Intraarterial delivery of microsphere therapy has been shown to be safe and effective in a variety of settings [12–28]. Examples include candidates for liver transplant, unresectable hepatocellular carcinoma (HCC) even with concurrent portal vein thrombosis, unresectable or recurrent cholangiocarcinoma, and liver-dominant metastases from colorectal cancer, breast cancer, renal cell carcinoma, pancreatic cancer, melanoma, and NETs even if tumors have been heavily pretreated.…”

Section: Selective Internal Radioembolization Of Malignant Liver Lesionsmentioning

confidence: 99%

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

Jadvar

2017

American Journal of Roentgenology

View full text Add to dashboard Cite

Objective This article reviews recent developments in targeted radionuclide therapy (TRT) approaches directed to malignant liver lesions, bone metastases, neuroendocrine tumors, and castrate-resistant metastatic prostate cancer and discusses challenges and opportunities in this field. Conclusion TRT has been employed since the first radioiodine thyroid treatment almost 75 years ago. Progress in the understanding of the complex underlying biology of cancer and advances in radiochemistry science, multimodal imaging techniques including the concept of “see and treat” within the framework of theranostics, and universal traction with the notion of precision medicine have all contributed to a resurgence of TRT.

show abstract

Section: Selective Internal Radioembolization Of Malignant Liver Lesionsmentioning

confidence: 99%

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

Jadvar

2017

American Journal of Roentgenology

View full text Add to dashboard Cite

show abstract

“…23 Despite some studies showing that this treatment is useful for liver cancer, it may not be appropriate for some patients, such as patients with poor liver reserve function or extrahepatic metastatic disease. 24 Determining the quality and quantity required for 90 Y is complicated, 25 and the high cost and limited supply limit its clinical use. 90 Y emits pure b --particles with a half-life of 64.1 h. Since 90 Y lacks c-emission, it is not easy to obtain any information about the positioning and biological distribution of 90 Y microspheres in patients by imaging after the administration of a therapeutic dose.…”

Section: Discussionmentioning

confidence: 99%

Preliminary Studies of ¹⁷⁷Lu-Diethylenetriamine Penta-Acetic Acid-Deoxyglucose in Hepatic Tumor-Bearing Mice

Zhou

Chen

Yang

et al. 2020

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Objective: The purpose of this study was to explore the potential use of 177 Lu-diethylenetriamine penta-acetic acid-deoxyglucose (177 Lu-DTPA-DG) as a radiopharmaceutical for hepatic tumor treatment. Methods: Lutetium-177 (177 Lu) was labeled with DTPA-DG by adding 2 mCi 177 LuCl 3 to 0.05 mg DTPA-DG (pH 5-6) at room temperature for 1 h. The quality of the 177 Lu-DTPA-DG solutions was determined by thinlayer chromatography and high-performance liquid chromatography. Cellular uptake studies with 18 Ffluorodeoxyglucose (FDG), 177 Lu-DTPA-DG and 177 Lu-DTPA and a blocking study with 1.0 mg d-glucose were performed. Biodistribution, imaging, and radiotherapy studies of 177 Lu-DTPA-DG were performed with the SMMC-7721 model. Results: 177 Lu-DTPA-DG had a high radiochemical purity (>97%). The cellular uptake of 177 Lu-DTPA-DG was much higher than that of the 177 Lu-DTPA. The biodistribution of 177 Lu-DTPA-DG demonstrated that the complex accumulated in the tumor with high tumor/blood and tumor/muscle ratios. The tumors in mice in the 177 Lu-DTPA-DG group clearly displayed the high uptake of 177 Lu-DTPA-DG. After radiotherapy with 177 Lu-DTPA-DG, tumor growth decreased, and the overall survival was longer than that in the 177 LuCl 3 group (268.58-17.96 mm 3 vs. 507.43-55.72 mm 3 , p = 0.002) and the normal saline group (268.58-17.96 mm 3 vs. 483.68-27.51 mm 3 , p < 0.05). Conclusions: This preliminary study suggests that 177 Lu-DTPA-DG has the potential to become a liver radiopharmaceutical agent and should be further investigated.

show abstract

“…The preferential arterial supply is known in human liver tumors [13, 14] and has previously been shown in a transgenic tumor model [8] in mice. In the present work, application of unlabeled ME-9F1 mAb occupied free CD146 epitopes on the endothelium and prevented binding of the subsequently injected fluorescent mAb in the liver and tumor.…”

Section: Discussionmentioning

confidence: 99%

Microsurgical Technique of Locoregional Injection into the Hepatic Artery in Tumor-Bearing Mice

Qian¹,

Strübing

Wang

et al. 2018

Eur Surg Res

View full text Add to dashboard Cite

Background: Intraarterial injection into the hepatic artery represents an important route for locoregional administration for the treatment of hepatic tumors. In the present work, we describe microsurgical methodology for injection into the hepatic artery in mice. The technique was recently used for analysis of the phenomenon of endothelial capture in liver tumors. Methods: Two different models of hepatic tumors in C57BL/6 mice were used. Tumors were induced by intrahepatic cell inoculation. The preferential blood supply of tumors was studied using blocking of bioavailability of nontumoral endothelial epitope and the subsequent injection of fluorescent endothelium-specific antibody. The selective intraarterial injection of labeled antibody was performed in tumor-bearing mice. The procedure addressed variations of vascular anatomy of the hepatic artery in mice and used direct intraarterial injection with dispensable catheterization. Results: Both experimental tumor models showed preferential blood supply from the hepatic artery. The technique of hepatic arterial injection was adapted and performed according to two major anatomic variations of the hepatic artery. Using this technique, the selective enrichment of labeled antibody to tumor and liver blood vessels, which were perfused during the first intravascular passage, was demonstrated. Conclusions: The experimental hepatic arterial injection in mice is a feasible but demanding microsurgical procedure. The choice of subsequent operation steps is dependent on the vascular anatomy of the hepatic artery which has two major variations in mice.

show abstract

Intra-Arterial Radionuclide Therapies for Liver Tumors

Cited by 42 publications

References 59 publications

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

Preliminary Studies of ¹⁷⁷Lu-Diethylenetriamine Penta-Acetic Acid-Deoxyglucose in Hepatic Tumor-Bearing Mice

Microsurgical Technique of Locoregional Injection into the Hepatic Artery in Tumor-Bearing Mice

Contact Info

Product

Resources

About

Intra-Arterial Radionuclide Therapies for Liver Tumors

Cited by 42 publications

References 59 publications

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment

Preliminary Studies of 177Lu-Diethylenetriamine Penta-Acetic Acid-Deoxyglucose in Hepatic Tumor-Bearing Mice

Microsurgical Technique of Locoregional Injection into the Hepatic Artery in Tumor-Bearing Mice

Contact Info

Product

Resources

About

Preliminary Studies of ¹⁷⁷Lu-Diethylenetriamine Penta-Acetic Acid-Deoxyglucose in Hepatic Tumor-Bearing Mice